Special Issue

Real-World Perspective on Effectiveness, Safety, and Costs of Orphan Medicines in Neurology

Message from the Guest Editors

Orphan drug can be defined as a medicine for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition that is rare (affecting not more than five in 10,000 people) or where the medicine is unlikely to generate sufficient profit to justify research and development costs.

In this Special Issue on "Real-World Perspective on Effectiveness, Safety, and Costs of Orphan Medicines in Neurology", we aim to publish outstanding contributions in the key fields covered by the journal, which will make a great contribution to the community.

Thus, we believe that the JPM is an excellent platform to support such overview on the current real-world knowledge and novelties regarding effectiveness, safety and costs or orphan medicines in neurology.

We hope that our special issue will draw the attention of the readers, scientists, stakeholders and clinicians in general.

Guest Editors

Prof. Dr. Dinko Vitezić

- 1. Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Krešimirova 42, 51000 Rijeka, Croatia
- Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, Braće Branchetta 20, 51000 Rijeka, Croatia

Dr. Andrej Belančić

- Department of Clinical Pharmacology, Clinical Hospital Centre Rijeka, Rijeka, Croatia
- 2. Department of Basic and Clinical Pharmacology with Toxicology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

Deadline for manuscript submissions

closed (25 March 2025)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/193240

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

